Status:
RECRUITING
Determination of the Optimal Volume of Liposomal Bupivacaine in Adductor Canal Block for Knee Joint Surgery
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University
Conditions:
Optimal Volume of Liposomal Bupivacaine
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
Building on Bayesian design methodologies from volume optimization studies of ropivacaine in shoulder surgery, this study pioneers the application of a seamless dose-finding strategy in knee ACB. Util...
Eligibility Criteria
Inclusion
- Patients undergoing elective general anesthesia for unilateral knee joint surgery.
- Patients who provide informed consent.
- Aged between 18 and 65 years old, regardless of gender.
- American Society of Anesthesiologists (ASA) physical status classification of Ⅰ to Ⅲ
- Body mass index (BMI) ≤ 35 kg/m².
Exclusion
- Femoral neuropathy.
- Coagulation dysfunction.
- Allergy to local anesthetics.
- Infection at the puncture site.
- History of chronic pain or opioid use.
- Pregnancy.
- Diabetes mellitus and peripheral neuropathy.
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT06942689
Start Date
June 1 2025
End Date
December 31 2027
Last Update
September 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanjing First Hospital
Nanjing, Jiangsu, China, 210006